These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3308975)

  • 1. Intravenous pinacidil in the acute treatment of hypertension.
    Rijk MC; Thien T
    J Clin Pharmacol; 1987 Jul; 27(7):468-74. PubMed ID: 3308975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pinacidil on blood pressure, plasma catecholamines and plasma renin activity in essential hypertension.
    Muiesan G; Fariello R; Muiesan ML; Christensen OE
    Eur J Clin Pharmacol; 1985; 28(5):495-9. PubMed ID: 3899669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of intravenous endralazine in essential hypertension.
    Hoffmann JJ; Thien T; van T'Laar A
    Br J Clin Pharmacol; 1983 Jul; 16(1):39-44. PubMed ID: 6349669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N"-Cyano-N-4-pyridyl-N'-1,2,2-trimethyl-propylguanidine, a new vasodilating agent: acute effect of blood pressure and pharmacokinetics in hypertensive patients.
    Kardel T; Hilden T; Carlsen J; Trap-Jensen J
    J Cardiovasc Pharmacol; 1981; 3(5):1002-7. PubMed ID: 6168845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomized, controlled trial comparing pinacidil to hydralazine in essential hypertension.
    Byyny RL; Nies AS; LoVerde ME; Mitchell WD
    Clin Pharmacol Ther; 1987 Jul; 42(1):50-7. PubMed ID: 3297468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between blood pressure, heart rate and plasma epinephrine, norepinephrine, angiotensin II concentrations, plasma renin activity during chronic guanfacine therapy in patients with essential arterial hypertension.
    Collart F; Staroukine M; Verniory A
    Acta Cardiol; 1985; 40(3):269-76. PubMed ID: 3895792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of antihypertensive, renal hemodynamic, and humoral effects of pinacidil and hydralazine monotherapy.
    Abraham PA; Halstenson CE; Matzke GR; Keane WF
    J Clin Hypertens; 1987 Dec; 3(4):439-51. PubMed ID: 3330986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator.
    Breen EG; Mulhall D; Keogh JA
    Eur J Clin Pharmacol; 1985; 28(4):381-6. PubMed ID: 4029244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.
    Ward JW; McBurney A; Farrow PR; Sharp P
    Eur J Clin Pharmacol; 1984; 26(5):603-8. PubMed ID: 6468476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension.
    Solomon RJ; Weinberg MS
    J Clin Hypertens; 1987 Dec; 3(4):589-95. PubMed ID: 3330989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pinacidil monotherapy for hypertension.
    Ward JW
    Br J Clin Pharmacol; 1984 Aug; 18(2):223-5. PubMed ID: 6487460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension.
    Goldberg MR; Rockhold FW; Offen WW; Dornseif BE
    Clin Pharmacol Ther; 1989 Aug; 46(2):208-18. PubMed ID: 2758730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study.
    Goldberg MR; Offen WW
    Drugs; 1988; 36 Suppl 7():83-92. PubMed ID: 3076140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary evaluation of pinacidil in hypertension.
    Ramsay LE; Freestone S
    Br J Clin Pharmacol; 1983 Sep; 16(3):336-8. PubMed ID: 6626426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute hemodynamic effects of pinacidil in hypertensive patients with and without propranolol pretreatment.
    Stone CK; Wellington KL; Willick A; Sullebarger JT; Liang CS
    J Clin Pharmacol; 1991 Apr; 31(4):333-41. PubMed ID: 2037705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute hemodynamic effects of pinacidil and hydralazine in essential hypertension.
    Carlsen JE; Kardel T; Lund JO; McNair A; Trap-Jensen J
    Clin Pharmacol Ther; 1985 Mar; 37(3):253-9. PubMed ID: 2857601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of long-term treatment of essential hypertension with guanfacine.
    Higuchi M; Overlack A; Stumpe KO
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):61S-64S. PubMed ID: 6994780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension.
    Carlsen JE; Kardel T; Jensen HA; Tangø M; Trap-Jensen J
    Eur J Clin Pharmacol; 1983; 25(4):557-61. PubMed ID: 6653652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive effects of pinacidil in patients with and without indomethacin pretreatment.
    Cinquegrani MP; Liang CS
    Clin Exp Hypertens A; 1988; 10(3):411-31. PubMed ID: 3359658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.
    Izzo JL; Licht MR; Smith RJ; Larrabee PS; Radke KJ; Kallay MC
    Am J Cardiol; 1987 Aug; 60(4):303-8. PubMed ID: 2887102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.